Akathisia, or acathisia, is a syndrome characterized by unpleasant sensations of "inner" restlessness that manifests itself with an inability to sit still or remain motionless, hence its origin in Ancient Greek α (a), [without, not] + κάθισις (káthisis), [sitting]. Its most common cause is as a side effect of medications, mainly neuroleptic antipsychotics especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupenthixol and zuclopenthixol) and butyrophenones (such as haloperidol (Haldol)), piperazines (such as ziprasidone), and rarely, antidepressants. Akathisia can also, to a lesser extent, be caused by Parkinson's disease and related syndromes. But all neuroleptic antipsychotic psychotropic drugs cause Parkinsonian like symptoms due to blockage of dopamine receptors in the nigrostriatal pathway of the brain.

Akathisia may range in intensity from a mild sense of disquiet or anxiety (which may be easily overlooked) to a total inability to sit still, accompanied by overwhelming anxiety, malaise, and severe dysphoria (manifesting as an almost indescribable sense of terror and doom). The condition is difficult for the patient to describe and is often misdiagnosed. When misdiagnosis occurs in antipsychotic neuroleptic-induced akathisia, more antipsychotic neuroleptics may be prescribed, potentially worsening the symptoms. High-functioning patients have described the feeling as a sense of inner tension and torment or chemical torture.

The presence and severity of akathisia can be measured using the Barnes Akathisia Scale.

Description

Healy, et al (2006), described the following regarding akathisia: tension, insomnia, a sense of discomfort, motor restlessness, and marked anxiety and panic. Increased labile affect can result, such as weepiness. Interestingly, in some people the opposite response to SSRIs occurs, in the form of emotional blunting; but sufficient clinical research has not yet been made in this area.

Jack Henry Abbot (1981) described the effects of akathisia produced by antipsychotic drugs:

In severe cases, akathisia can be so tormenting that the patient is compelled to take action, such as suicide attempts.

Treatment non-compliance is a common consequence of neuroleptic-induced akathisia. At the extreme end of non-compliance, patients who have been treated with neuroleptic antipsychotics for psychotic episodes or prochlorperazine for nausea may rarely run away from hospitals or emergency rooms due to this disconcerting sensation.

Causes

Akathisia is most often seen as a side effect of antipsychotic medications, but has other causes as well:

• Non-sedating antipsychotics such as haloperidol (Haldol), droperidol, pimozide, trifluoperazine, amisulpride, risperidone, and aripiprazole (Abilify). Less common in sedating antipsychotics such as zuclopenthixol (Cisordinol) or chlorpromazine where anticholinergic and antihistaminergic effects counteract akathisia to a degree.
• SSRIs, such as fluoxetine (Prozac). It has also been documented with the use of paroxetine (Paxil). Akathisia has been studied as the mechanism by which SSRI-induced suicidality occurs.
• Other antidepressants, such as the tricyclics and trazodone (Desyrel).
• Certain anti-emetic drugs, particularly the dopamine blockers, such as metoclopramide (Reglan) and prochlorperazine (Compazine).
• Opiate withdrawal.

The 2006 UK study by Healy, Herxheimer, and Menkes observed that akathisia is often miscoded in antidepressant clinical trials as "agitation, emotional lability, and hyperkinesis (overactivity)". The study further points out that misdiagnosis of akathisia as simple motor restlessness occurs, but that this is more properly classed as dyskinesia. Healy, et al., further show links between antidepressant-induced akathisia and violence, including suicide, as akathisia can "exacerbate psychopathology." The study goes on to state that there is extensive clinical evidence correlating akathisia with SSRI use, showing that approximately ten times as many patients on SSRIs as those on placebos showed symptoms severe enough to drop out of a trial (5.0% compared to 0.5%).

Treatment

Treatment includes the discontinuation or reduction of dose of the causative agent.

The most common treatment for antipsychotic akathisia is the anticholinergic medication benztropine (Cogentin). But since benztropine is for extrapyramidal side effects such as muscle spasms, muscle stiffness and tremors it is not effective in treating akathisia which is not a true extrapyramidal side effect. Other anticholinergic medications such as diphenhydramine may also be used in the treatment of akathisia.

Akathisia can be reduced by administering other drugs, though effectiveness can vary with more severe cases resistant to most drug treatment. Benzodiazepines like clonazepam (Klonopin) are effective. Some consider the drug of choice for the treatment of akathisia to be beta-blockers such as propranolol (Inderal) or metoprolol. The antihistamine cyproheptadine is also effective, though with shorter effect than beta blockers.

One study showed that vitamin B₆ is effective for the treatment of neuroleptic-induced akathisia.

See also

• Agitation (emotion)
• Anxiety
• Psychomotor agitation
• Restless legs syndrome

References

External links

• DSM-IV: Neuroleptic Induced Acute Akathisia at behavenet.com
• Information on treating this condition and copies of original research papers at akathisiasupport.org
• Nasrallah H, Brecher M, Paulsson B (2006). "Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania". Bipolar Disord 8 (5 Pt 1): 467–74.